Vaquero J, Zurita M, Morales C, Oya S, Coca S
Neurosciences Research Unit of the Mapfre-Medicine Foundation, Laboratory of Experimental Neuro-oncology, Puerta de Hierro Clinic, Autonomous University, Madrid, Spain.
J Neurooncol. 2000;46(1):11-6. doi: 10.1023/a:1006347919565.
The aim of this study is to investigate the usefulness of a vascular endothelial surface score (VESS) and MIB-1 labeling index (MIB-1 LI), in a defined series of glioblastomas, as biological markers with prognostic significance of survival. Tumor tissue and survival were studied in a series of 38 patients with glioblastoma, previously treated by surgical resection and radiotherapy. For each tumor, immunohistochemical and morphometric studies were performed in order to study MIB-1 LI, and VESS, expressed as the CD-34 immunostained endothelial surface per 1000 tumor cells. The survival for the entire patient population of the series was 48.1+/-14.1 weeks, and the mean VESS for the tumors of the series ranged from 16.7 to 107 microm2 per 1000 tumor cells (mean: 38.7+/-18.2). Factors such as age or MIB-1 LI were not significatively associated with survival, but the median survival for the 18 patients with a VESS less than 35 was 50.7+/-3.7 weeks, versus 45.9+/-2.8 weeks for the 20 patients showing a VESS higher than 36 (p < 0.05). Our present results suggest that tumor VESS, expressed as the CD-34 immunostained endothelial surface per each 1000 tumor cells, may have usefulness, as angiogenic-related factor influencing survival, in patients with glioblastoma.
